188 180

Cited 5 times in

Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study

Authors
 Yu Jin Kim  ;  Jae Hee Cheon  ;  Sang Kil Lee  ;  Jie Hyun Kim  ;  Yong Chan Lee 
Citation
 JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.25(4) : 583-588, 2010 
Journal Title
 JOURNAL OF KOREAN MEDICAL SCIENCE 
ISSN
 1011-8934 
Issue Date
2010
MeSH
Adult ; Aged ; Aged, 80 and over ; Alanine/analogs & derivatives* ; Alanine/therapeutic use ; Anti-Ulcer Agents/therapeutic use* ; Endoscopy, Gastrointestinal/adverse effects* ; Famotidine/therapeutic use* ; Histamine H2 Antagonists/therapeutic use* ; Humans ; Iatrogenic Disease ; Male ; Middle Aged ; Pilot Projects ; Prospective Studies ; Quinolones/therapeutic use* ; Receptors, Histamine H2/metabolism ; Stomach Ulcer/drug therapy* ; Stomach Ulcer/etiology* ; Stomach Ulcer/pathology ; Wound Healing
Keywords
H2 Receptor Antagonist ; Rebamipide ; Stomach Ulcer, Endoscopic Mucosal Resection
Abstract
Endoscopic mucosal resection (EMR) results in the formation of iatrogenic gastric ulcers and the optimal treatments for such ulcers are still unclear. We aimed to evaluate the efficacy of rebamipide in the management of EMR-induced ulcers by comparing it with an H(2) receptor antagonist. After EMR, patients were randomly assigned into either rebamipide or famotidine groups. All patients received a one-week lansoprazole 30 mg q.d. therapy followed by three-week famotidine (20 mg b.i.d.) or rebamipide (100 mg t.i.d.) therapy. Four weeks after the treatments, ulcer sizes, stages, bleeding rates, and ulcer-related symptoms were compared using endoscopy and a questionnaire. A total of 63 patients were enrolled in this study. Finally, 51 patients were analyzed, 26 in rebamipide and 25 in famotidine group. Baseline characteristics were not significantly different between the two groups. Four weeks after EMR, the two groups were comparable in terms of ulcer reduction ratio (P=0.297), and ulcer stage (P=1.000). Moreover, no difference was observed with regard to ulcer-related symptoms, drug compliance, adverse drug event rates, and bleeding rates. Our data suggest that rebamipide is not inferior to famotidine in healing iatrogenic gastric ulcers, and could be a therapeutic option in the treatment of such ulcers.
Files in This Item:
T201000720.pdf Download
DOI
10.3346/jkms.2010.25.4.583
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Yoo Jin(김유진)
Kim, Jie-Hyun(김지현) ORCID logo https://orcid.org/0000-0002-9198-3326
Lee, Sang Kil(이상길) ORCID logo https://orcid.org/0000-0002-0721-0364
Lee, Yong Chan(이용찬) ORCID logo https://orcid.org/0000-0001-8800-6906
Cheon, Jae Hee(천재희) ORCID logo https://orcid.org/0000-0002-2282-8904
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/100788
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse